Evidence map›Paper›PMID 21788626›Full record

ArticleDiabetes care2011

Cross-sectional and longitudinal changes of glucose effectiveness in relation to glucose tolerance: the insulin resistance atherosclerosis study.

Carlos Lorenzo, Lynne E Wagenknecht, Andrew J Karter, Anthony J G Hanley, Marian J Rewers, Steven M Haffner

Abstract read
In one paragraph

Article in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Carlos LorenzoDivision of Clinical Epidemiology, University of Texas Health Science Center, San Antonio, TX, USA. lorenzo@uthscsa.edu
Lynne E Wagenknecht
Andrew J Karter
Anthony J G Hanley
Marian J Rewers
Steven M Haffner
Kaiser Permanente · USThe University of Texas Health Science Center at San Antonio · USUniversity of Colorado Health · USUniversity of Toronto · CAWake Forest University · US

Funding

ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PLISZKA, STEVEN R. · 1985 to 2008
$23.1M
Ethnic Disparities in Diabetes ComplicationsR01DK065664 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI KARTER, ANDREW JOHN · 2004 to 2008
$3.3M
Diabetes and Aging in a Multi-Ethnic PopulationR01DK081796 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI HUANG, ELBERT S., KARTER, ANDREW JOHN · 2009 to 2013
$2.9M
Educational Disparities in Diabetes ComplicationsR01HD046113 · NICHD · KAISER FOUNDATION RESEARCH INSTITUTE · PI KARTER, ANDREW JOHN · 2003 to 2006
$1.6M
INSULIN RESISTANCE AND ATHEROSCLEROSIS STUDY (IRAS)U01HL047887 · NHLBI · WAKE FOREST UNIVERSITY · PI WAGENKNECHT, LYNNE E · 1991 to 1999
–
INSULIN RESISTANCE, HYPERGLYCEMIA AND ATHEROSCLEROSISU01HL047889 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI SELBY, JOE V · 1991 to 1999
–
INSULIN RESISTANCE AND ATHEROSCLEROSIS STUDY (IRAS)U01HL047890 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERGMAN, RICHARD N. · 1991 to 1999
–
INSULIN RESISTANCE AND CARDIOVASCULAR DISEASEU01HL047892 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1991 to 1999
–
INSULIN RESISTANCE AND ATHEROSCLEROSIS STUDY (IRAS)U01HL047902 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SAAD, MOHAMMED F · 1991 to 1999
–
NCRR NIH HHS M01 RR001346NCRR NIH HHS M01-RR01346NCRR NIH HHS M01-RR431NHLBI NIH HHS HL-47887NHLBI NIH HHS HL-47889NHLBI NIH HHS HL-47890NHLBI NIH HHS HL-47892NHLBI NIH HHS U01 HL047892NHLBI NIH HHS U01 HL047902NICHD NIH HHS R01 HD046113NIDDK NIH HHS R01 DK065664NIDDK NIH HHS R01 DK081796
6 · The paper itself

Abstract

objectiveGlucose effectiveness (S(G)), the capacity of glucose to enhance its own disposition, is an independent predictor of future diabetes. However, there are data on cross-sectional and longitudinal changes of S(G) and its components, basal insulin effect on S(G) (BIE) and S(G) at zero insulin (GEZI), but the natural course of S(G) has not been described in a large population. RESEARCH DESIGN AND

methodsS(G) was measured at baseline in 1,265 participants (aged 40-69 years) and at the 5-year examination in 827 participants in the Insulin Resistance Atherosclerosis Study (IRAS) using the frequently sampled intravenous glucose tolerance test. None of these participants were treated with glucose-lowering agents.

resultsIn cross-sectional analyses, S(G), BIE, and GEZI deteriorated with worsening of glucose tolerance (P < 0.001 for all three associations). In longitudinal analyses among subjects with normal glucose tolerance (NGT) at baseline, S(G), BIE, and GEZI declined in those who progressed to impaired glucose tolerance (IGT) or diabetes (P < 0.001 for all three measures). More modest longitudinal changes were demonstrated in individuals with IGT. The transition back to NGT (as opposed to no change) compared with the transition to diabetes was statistically significant for S(G) (P = 0.049) and BIE (P = 0.042) and was not a statistically significant trend for GEZI (P = 0.332). In individuals with diabetes, only BIE had a significant decline (P = 0.003).

conclusionsS(G), BIE, and GEZI decline in subjects whose glycemic status worsens. S(G) and GEZI deteriorate more in the initial stages of the disease process.

Indexed as

AdultAgedAtherosclerosisBlood GlucoseCross-Sectional StudiesFastingFemaleGlucose IntoleranceHumansInsulinInsulin ResistanceLongitudinal StudiesMaleMiddle AgedBlood GlucoseInsulin

Identifiers

PMID21788626
PMCPMC3161274
OpenAlexW2147841413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.